Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Listed as NCT00210314, this PHASE2 trial focuses on Lymphoma, B Cell and remains completed. Sponsored by International Extranodal Lymphoma Study Group (IELSG), it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- International Extranodal Lymphoma Study Group (IELSG)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Bellinzona, Switzerland